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INTRODUCTION
The Inflammatory Bowel Diseases (IBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDU) are increasing in incidence and prevalence, notably in the paediatric population. 1 Paediatric care has been revolutionised in the last decade by the widespread introduction of anti-tumour necrosis factor (anti-TNF) therapy, both infliximab (IFX) and adalimumab (ADA); registration clinical trials have shown these agents to be effective where other therapies have failed. 2, 3 Paediatric onset IBD (PIBD) tends to be more extensive at diagnosis and aggressive in behaviour 4, 5 and use of anti-TNF therapy is proportionately greater in the paediatric population compared to adults (20% in adolescents vs 8% in adults in one case control study) 6 . IFX and ADA have been licensed for use in PIBD in the UK since 2010 and 2013 respectively; UK survey data has demonstrated effectiveness in treating refractory disease whilst highlighting the potential for serious side effects. 7, 8 Scottish data on 132 PIBD patients treated with biologics over a decade show response rates of 87% with IFX (48% remission) and 76% with ADA (35% remission) replicating safety issues, especially serious infection. 9 The UK IBD audit is a national gastrointestinal audit first commenced in 2006 (reporting in 2008). Reports are available online at www.rcplondon.ac.uk/ibd. Data has previously been published on the outcomes of paediatric and adult patients with UC. 10, 11 We aimed to collect data on anti-TNF therapies in UK PIBD practice to assess effectiveness, safety and appropriate use (according to national guidelines) in clinical practice. Unselected, large scale national data will help quantify and categorise adverse events where real life clinical data is lacking.
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MATERIALS AND METHODS
Sites (either a single hospital or a represented health board or trust) were eligible to participate in the audit if they prescribe and administer anti-TNF therapies to their patients with IBD, on a voluntary basis. A total of 37 sites participated, including 23 of 25 specialist PIBD sites, representing a broad subset of PIBD patients across the UK.
Children with a diagnosis of IBD who were aged 18 years or younger when newly started on anti-TNF therapy for IBD from 12/09/11 were eligible for inclusion. Patients already on anti-TNF therapy prior to this date were excluded. Data was collected prospectively and entered into a bespoke web based database, with security maintained through local site codes and the lead clinician for the site authorising local access. All treatment decisions and data entry were at the discretion of the treating physician. Data capture for the results included here ended on 28/02/14.
Demographic details were pseudo-anonymised at the point of data entry and identifiable only to the participating site. IBD disease details were phenotyped according to Montreal criteria for disease location and behaviour. 12 Physician Global Assessment (PGA), Paediatric Crohn's Disease Activity Index (PCDAI) or Paediatric Ulcerative Colitis Activity Index (PUCAI) scores were collected at initial and follow-up treatments, along with details of comorbidities and any surgery. 13, 14, 15 A full list of all data items collected is available on request.
Acute infusion reactions were as decided by the treating clinical team responsible for the patient; no specific guidance on specific timing was given to teams. Each follow-up treatment relates to an initial submission and records outcome as intention to continue or Copyright © ESPGHAN and NASPGHAN. All rights reserved. stop; response with or without remission using reduction in PCDAI/PUCAI or Harvey Bradshaw Index (HBI). 16 Unlimited numbers of follow-up treatments are permitted and any adverse events recorded. Poor response was used to describe those patients with no or limited response to anti-TNF treatment, which included primary non-responders.
Details of IBD related surgery can be added at any time, along with any escalation of treatment at each initial or follow-up treatment. Patient Reported Outcome Measures (PROM) data was collected using the IMPACT-III questionnaire [17] [18] [19] at initiation and subsequently.
Some children received treatment with multiple biologics resulting in more initial treatments than patients. Since the number of submissions per patient is variable (e.g. Data were collected on disease type and severity as well as previous therapies to assess prescribing against these criteria.
Selected data, including demographics, disease location and response to treatment were compared to data reported in the adult arm of the audit from the same time period, which can be seen at www.rcplondon.ac.uk/ibd. Chi-squared test and the kappa statistic were used to examine categorical data; the MannWhitney U test was used to examine continuous data; Kolmogorov-Smirnov (KS) test was used to analyse PROM data. Kappa statistic is expressed as per the boundaries described by Landis and Koch; range is from 'poor/slight' agreement (Κ ≤0.2) through 'fair', 'moderate' and 'substantial', to 'almost perfect' agreement (Κ 0.81-1.00). A p value of <0.05 was considered statistically significant.
ETHICAL CONSIDERATIONS
As an audit of clinical practice, ethical permission was not applied for.
RESULTS

Overview
By 28/02/14, demographic submissions were entered on 817 individual paediatric patients; 156 patients with no initial treatment details entered were excluded leaving 661 patients with 746 initial treatments (some patients were treated with more than one antiCopyright © ESPGHAN and NASPGHAN. All rights reserved. infrequently done (17% patients). This is despite patients going on to receive maintenance therapy after their induction course. We highlight the need for formal postinduction assessment of response to determine the need for on-going treatment and suggest a validated scoring system as the best method. Failure to do this formally is highly concerning; patients may continue to receive treatment that is failing or not have appropriate investigations performed e.g. trough level determination.
Complete accrual of all anti-TNF use, effectiveness and safety has been published in a nationwide Scottish PIBD registry study, but this only represents 8% of the UK paediatric population. 9 Lower remission rates of 48% and 36% for IFX and ADA respectively were reported here but the period studied was longer 2000 -2010, perhaps reflecting early use of anti-TNF when current standard practice, such as maintenance rather than episodic treatment and dose optimisation, was not in place. 9 A previous UK survey of adalimumab for paediatric CD reported a remission rate of 61% at follow-up 8 and the RESEAT study a 65-71% clinical response rate at 3-12 months of ADA therapy in paediatric CD, 24 which are comparable despite our low documentation rate.
There is a clear discrepancy between PGA and PCDAI scores. Documentation of PCDAI at follow-up was low, as in previous studies, thought potentially due in part to the inclusion of items that are less readily obtained such as height velocity, perianal examination and laboratory indices. 15, 25 Formal documentation of such data can be seen as a low priority in busy clinical practice. PCDAI was less frequently recorded than PUCAI here, which may support the theory that a simpler score is better used. Recently, the weighted PCDAI (wPCDAI) has been proposed as an alternative measure to the PCDAI and shown to have validity despite the exclusion of haematocrit, abdominal examination and height velocity as parameters. 26 Replacing PCDAI with wPCDAI in subsequent rounds of the audit may encourage increased completion and thereby facilitate more objective clinical assessment and aid decision making. An app to allow easy calculation of wPCDAI and documentation was produced as a result of this study.
The PUCAI appeared to have better correlation with PGA than PCDAI, in keeping with other studies specifically designed to test this which show excellent agreement. 15 There was a significant reduction in the need for drainage of perianal abscess after initiation with anti-TNF. We note that time periods pre and post initiation were not equal or defined, limiting the strength of any conclusions drawn from this, but we know that perianal disease is recognised as a debilitating CD phenotype and anti-TNFs have been shown to be an effective treatment in large studies. 27 The rate of colectomy in UC patients at 16% is in keeping with adult studies 28, 29 , rate of colectomy post anti-TNF in IBDU patients is notable at 21% but numbers are small (4/19).
Although the follow-up period is relatively short (max 2.46 years), the large number of patients allows us some confidence in the short term safety profile of the anti-TNF therapies, as 2287 infusions and 302 years of patient follow-up are represented. Infection was the commonest adverse event, in keeping with other published studies 30, 9 and whilst risks are minimised where possible, total prevention is not achievable. Despite safety concerns about the use of combination therapy and lymphoma risk, it is interesting to note that the majority of patients in this cohort were on combination therapy. Recently published registry data from a very large cohort of paediatric patients (some from the UK) have shown no increased risk of malignancy during longer term follow up, Copyright © ESPGHAN and NASPGHAN. All rights reserved.
supporting the good safety profile of infliximab, 31 as with previous anti-TNF safety data. 32 Screening practice is variable; exclusion of TB infection is an obligatory part of guidelines so there remains room for improvement in the final unscreened 3%. 33, 34 The risk of hepatitis B reactivation is well known but despite this less than half of patients were screened, highlighting a need to improve on this.
The shortened time from diagnosis to starting anti-TNF in the paediatric population compared to adults is striking; it suggests aggressive progression of disease and rapid cycling though medical therapeutic options, although potentially reflects poorer tolerance of standard treatments and the context of aiming for steroid free remission as quickly as possible to minimise impact on growth, puberty and education.
It is difficult to draw any meaningful conclusion regarding impact on quality of life (QoL) due to the small numbers of documented PROMs. Completion in subsequent audit rounds should be promoted as improvement in QoL is an important outcome and cannot be assumed from other markers of response. Of note, significant improvement in QoL using IMPACT 3 in paediatric patients has been recently documented in a formal clinical study. 35 The main limitation of this study is the variability in completeness of data capture, reflected in the changing denominator for different categories of data. This audit relies on clinical centres finding time to enter patient data and it is often only possible for them to supply the minimum data set. By comparison it is a major undertaking to capture all biological usage and outcomes in a PIBD population. Ongoing national collaboration would be the best way to achieve this quickly and meaningfully. 
